C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) Overview
  3. Therapeutics Development
  4. Pipeline Products for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Overview
  5. Pipeline Products for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Comparative Analysis
  6. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Therapeutics under Development by Companies
  7. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Therapeutics under Investigation by Universities/Institutes
  8. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Companies
  13. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Investigation by Universities/Institutes
  14. C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Companies Involved in Therapeutics Development
  • Axikin Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pharmaxis Limited
  • Toray Industries, Inc.

For more information visit http://www.researchandmarkets.com/research/9cdjnk/cc_chemokine

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs